HK2 and glioblastoma: In this regard, encouraging results derived in 2016 from the study of Vartanian A. et al., who have targeted hexokinase 2 (hk2) to sensitize U87 and primary GBM cells and a xenograft GBM model subjected to combined radio-chemotherapy with TMZ treatment [60].